Cadila Healthcare has reported results for third quarter ended December 31, 2011.
The company has posted a fall of 4.40% in its net profit to Rs 134.21 crore for the quarter ended December 31, 2011 as compared to Rs 140.38 crore for the same quarter in the previous year. However, total income has increased by 22.38% to Rs 878.93 crore for quarter under review as compared to Rs 718.18 crore for the quarter ended December 31, 2010.
On the consolidated basis, the company has posted a fall of 7.90% in its net profit at Rs 149.21 crore for the quarter ended December 31, 2011 as compared to Rs 162.01 crore for the same quarter in the previous year. However, total income has increased by 19.81% at Rs 1401.44 crore for the quarter under review as compared to Rs 1169.75 crore year ago.
Cadila Pharmaceuticals focuses on various areas, such as formulations (human & veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1505.20 |
Dr. Reddys Lab | 5922.45 |
Cipla | 1339.45 |
Zydus Lifesciences | 983.05 |
Lupin | 1609.85 |
View more.. |